Sepsis in 2026: from bundles to biology. A critical review.
文献摘要
Sepsis remains associated with a substantial burden of morbidity and mortality despite more than two decades of Surviving Sepsis Campaign (SSC) recommendations. The 2026 update reinforces early recognition, resuscitation, timely antimicrobial therapy, source control, and reassessment, yet the benefit of increasingly intensive implementation of standardized measures may be approaching a ceiling. A central limitation is treating sepsis as a homogeneous entity despite the wide variation in etiologies, host susceptibility, immune responses, and clinical trajectories. Artificial intelligence, host-response biomarkers, rapid microbiological diagnosis, and pharmacokinetic/pharmacodynamic optimization provide new opportunities to shorten the time to effective intervention. In parallel, transcriptomic, genomic, and routine clinical data can identify subphenotypes and endotypes associated with different prognoses and potentially different treatment responses. Secondary analyses of clinical trials illustrate how an intervention that is neutral overall may be beneficial in biologically defined subgroups. The next step should combine SSC bundles with biological stratification, adaptive trial designs, and point-of-care tools capable of matching treatment to patient profile in real time. This review proposes a transition from standardized sepsis management toward precision medicine: the right treatment for the right patient at the right time.